NASDAQ$ATRC

Atricure Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Reported strong revenue growth driven by global performance and strategic investments with meaningful operating leverage.

AtriCure reported a strong third quarter with worldwide revenue increasing by 18.1% year-over-year to $98.3 million. The company experienced growth in both U.S. and international markets, driven by adoption of their products. They also reported a net loss of $9.1 million, an improvement from the previous year, and a positive adjusted EBITDA of $4.7 million.

  • Worldwide revenue increased 18.1% year-over-year to $98.3 million.
  • U.S. revenue increased 17.1% year-over-year to $81.7 million.
  • International revenue increased 23.2% year-over-year to $16.6 million.
  • Adjusted EBITDA was positive at $4.7 million, an improvement of $5.4 million year-over-year.

Headline financials

Total Revenue

$98.3M

Previous: $83.2M+18.1%
EPS (adj)

-$0.20

Previous: -$0.27+25.9%
Gross Margin

75.2%

Previous: 74.1%+1.5%
Adjusted EBITDA

$4.7M

Previous: -$735K+739.5%
Capital Expenditures

-$9.21M

Previous: -$12.7M+27.5%
Free Cash Flow

-$18.3M

Previous: -$25M+26.9%
Net Income

-$9.06M

Previous: -$12.3M+26.2%
Operating Income

-$8.09M

Previous: -$10.7M+24.6%
Gross Profit

$73.9M

Previous: $61.7M+19.7%
Cash & Equivalents

$80.6M

Previous: $48.8M+65.1%
Total Assets

$600M

Previous: $582M+3.2%
R&D Expense

$20.4M

No prior period
Stock-Based Comp

$8.66M

Previous: $7M+23.7%

Revenue & EPS history

Atricure · Revenue · Quarterly

$98.3M

Q3 2023+18.1%vs Q3 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Atricure · $93.5M total across 8 segments · Q1 2023

  • Appendage Management (U.S.)
    $32.3M
  • Open Ablation (U.S.)
    $25.1M
  • Pain Management (U.S.)
    $11.1M
  • Minimally Invasive Ablation (U.S.)
    $9.64M
  • Open Ablation (International)
    $7.29M
  • Appendage Management (International)
    $5.92M
  • Minimally Invasive Ablation (International)
    $1.87M
  • Pain Management (International)
    $228K

Forward guidance

Full year 2023 revenue is projected to be $394 million to $396 million, reflecting growth of approximately 19% to 20% over full year 2022. Management now expects full year 2023 positive adjusted EBITDA of approximately $18 million to $20 million, and full year 2023 adjusted loss per share of approximately $0.74 to $0.76.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.7%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.3%

Avg return

30 days after

48%

31 / 64 earnings

Positive

+21.1%

Q3 2024

Best reaction

-13.7%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.0%-10.5%-7.9%
Q4 2025-2.3%-3.6%-11.5%
Q3 2025-3.7%-7.6%+1.9%
Q1 2025-13.7%-16.1%-0.2%
Q4 2024-6.5%-9.8%-21.4%
Q3 2024+21.1%+16.6%+25.8%
Q2 2024-1.8%+0.4%+17.6%
Q1 2024-7.9%-8.4%-6.6%
Q4 2023+0.6%+1.4%-1.2%
Q3 2023+5.6%+9.3%+5.6%
Q2 2023+8.2%+3.8%-14.6%
Q1 2023+7.1%+7.1%+1.5%
Q4 2022+5.3%-1.3%-5.9%
Q3 2022-4.2%-5.9%+9.1%
Q2 2022+1.1%+4.3%-11.9%
Q1 2022-2.6%-17.8%-21.4%
Q4 2021+5.8%-3.8%+2.2%
Q3 2021+10.0%+9.2%-16.0%
Q2 2021-2.5%-5.4%-8.6%
Q1 2021+5.8%+16.8%+11.5%
Q4 2020-4.3%+0.1%-4.3%
Q3 2020+0.2%+6.8%+25.8%
Q2 2020-7.2%-10.7%-8.8%
Q1 2020+10.0%+4.7%+22.0%
Q4 2019-3.8%-10.1%-37.9%
Q3 2019-2.8%+4.4%+8.7%
Q2 2019+1.3%-0.3%-13.9%
Q1 2019+4.8%+7.4%+5.5%
Q4 2018-5.6%-8.4%-17.8%
Q3 2018-1.4%+0.7%+5.3%
Q2 2018+11.2%+7.2%+20.6%
Q1 2018+9.5%+7.8%+18.2%
Q4 2017+5.5%+1.9%+11.2%
Q3 2017-8.7%-12.3%-13.6%
Q2 2017+3.0%-0.4%-7.8%
Q1 2017+9.4%+5.5%+2.0%
Q4 2016+4.9%-5.5%+1.1%
Q3 2016+7.3%+9.0%+17.5%
Q2 2016-10.7%-4.2%+4.8%
Q1 2016-10.4%
Q4 2015-5.5%
Q3 2015-0.7%
Q2 2015+14.5%
Q1 2015+7.6%
Q4 2014-4.4%
Q3 2014+2.8%
Q2 2014-4.4%
Q1 2014-2.3%
Q4 2013-0.9%
Q3 2013+1.1%
Q2 2013+0.9%
Q1 2013+9.1%
Q4 2012+5.6%
Q3 2012+20.3%
Q2 2012-6.7%
Q1 2012-5.1%
Q4 2011-4.7%
Q3 2011-5.0%
Q2 2011-13.2%
Q1 2011+2.6%
Q4 2010+2.6%
Q3 2010-0.6%
Q2 2010-0.4%
Q1 2010-1.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro